There is increasing evidence for the use of hyperbaric oxygen therapy (HBOT) in selected patients with chronic diabetic foot ulcers ([@B1]). However, several issues still need to be answered, including health economics.

In an editorial commenting on our study, Lipsky and Berendt ([@B2]) reported costs between \$50,000 and \$200,000 for a full course of HBOT treatment in the U.S. Van der Staal et al. ([@B3]) report significantly lower cost/reimbursement in the Netherlands at €6,916 for 40 HBOT sessions. Our Hyperbaric Centre in the southern part of Sweden is reimbursed €9,462 for 40 HBOT sessions, whereas at another Swedish center, the same treatment schedule is reimbursed with €21,505. It must further be stated that these European figures only include HBOT. Accompanying expenses such as traveling and hotel costs are not included. In summary, the cost of a full course HBOT treatment for diabetic foot ulcer varies considerably from one center to another and might depend on set-up costs, ongoing costs, reimbursement systems, and number of patients treated per center.

Of more importance than the actual cost is the full health economical evaluation of a treatment. Some health economic analyses evaluating the cost-effectiveness of HBOT in diabetic foot ulcer treatment have been published, but they are limited by deficient primary clinical data and should be interpreted with caution ([@B4]--[@B6]). Still, these studies suggest a potential cost-effectiveness of HBOT, i.e., a crude analysis of the small but high-quality double-blind randomized clinical trial by Abidia et al. ([@B5]), only taking HBOT and dressing costs into account, suggests a saving of £2,960 per patient during the 1st year of follow-up ([@B4]).

However, the cost-effectiveness of HBOT could not be considered as established as long as robust health economic data---based on evaluation of large placebo-controlled randomized clinical trials evaluating the effect of HBOT as adjunctive treatment in a selected and specified population of patients with chronic diabetic foot ulcers---is lacking. The health economic analysis of HBOT in the setting of the Hyperbaric Oxygen Therapy in Diabetics with Chronic Foot Ulcers (HODFU) study is ongoing, hopefully making some more information available.
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